推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 北京市食品藥品監(jiān)督管理局發(fā)布的《關(guān)于進(jìn)一步加強(qiáng)中藥飲片生產(chǎn)監(jiān)管的通知》要求，中藥飲片企業(yè)內(nèi)部應(yīng)對(duì)中藥材、輔料與藥包材實(shí)施批號(hào)管理，實(shí)現(xiàn)按批號(hào)進(jìn)行追蹤，嚴(yán)厲打擊無證、超范圍生產(chǎn)銷售中藥飲片行為。對(duì)于檢驗(yàn)中存在套用、篡改、偽造檢驗(yàn)結(jié)果或數(shù)據(jù)、冒用檢驗(yàn)圖譜或未按照檢驗(yàn)規(guī)程規(guī)范檢驗(yàn)的，依法從重處理，情節(jié)嚴(yán)重的作為藥品GMP嚴(yán)重缺陷，收回《藥品GMP證書》。
通知提出，中藥飲片生產(chǎn)企業(yè)不得以中藥飲片生產(chǎn)者的身份從事其他生產(chǎn)經(jīng)營(yíng)行為，在批準(zhǔn)的《藥品生產(chǎn)許可證》、《藥品GMP證書》的場(chǎng)地、設(shè)施、設(shè)備范圍內(nèi)，未經(jīng)批準(zhǔn)不得從事與飲片研究、生產(chǎn)、銷售無關(guān)的行為。加強(qiáng)中藥材、炮制用輔料和藥包材的溯源管理，中藥飲片生產(chǎn)企業(yè)必須嚴(yán)格按照藥品GMP相關(guān)要求和品種的工藝規(guī)程組織生產(chǎn)，炮制全程必須在核準(zhǔn)的廠房?jī)?nèi)完成，批生產(chǎn)記錄應(yīng)及時(shí)、真實(shí)與完整記錄炮制過程。
通知明確，北京各區(qū)局、直屬分局應(yīng)將中藥飲片生產(chǎn)企業(yè)納入重點(diǎn)監(jiān)管范圍，將飛行檢查與突擊檢查作為監(jiān)管的常規(guī)手段。依法依規(guī)從嚴(yán)查處中藥飲片生產(chǎn)企業(yè)違法違規(guī)行為，涉嫌犯罪的，及時(shí)移送公安機(jī)關(guān)追究刑事責(zé)任。北京市食品藥品監(jiān)督管理局亦將組織中藥飲片生產(chǎn)企業(yè)的飛行檢查，并對(duì)區(qū)局和直屬分局工作進(jìn)行督導(dǎo)。
